Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore safety, tolerability, including the maximum tolerated
dose, and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory
Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).